DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers

Pawan Jolly, P. Damborsky, N. Madaboosi, R.R.G. Soares, V. Chu, J.P. Conde, J. Katrlik, Pedro Estrela

Research output: Contribution to journalArticle

31 Citations (Scopus)
179 Downloads (Pure)

Abstract

Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed in parallel, were developed in a microfluidic device and tested for the detection of free Prostate Specific Antigen (fPSA). A secondary antibody (Aptamer–Antibody Assay) or a lectin (Aptamer–Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor progression is associated with changes in fPSA glycosylation. With these approaches, we can potentially detect 0.5 ng/mL of fPSA and 3 ng/mL of glycosylated fPSA using Sambucus nigra (SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of biomarkers, thus providing a good alternative to standard antibody-based immunoassays with significant impact in medical diagnosis and prognosis.
Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalBiosensors and Bioelectronics
Volume79
Early online date19 Dec 2015
DOIs
Publication statusPublished - 16 May 2016

Keywords

  • microfluidics
  • DNA aptamers
  • glycoprofiling
  • sandwich assay
  • ELISA
  • Prostate cancer

Fingerprint Dive into the research topics of 'DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers'. Together they form a unique fingerprint.

  • Projects

  • Cite this